Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210383233/en/
The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed.
“This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Microbiome, Ferring Pharmaceuticals. “This collaboration is a successful example of our strategy to use external innovation to build our pipeline complementary to our in-house research; and we aim to do further collaborations to build a vibrant research community.”
Tomas de Wouters, CEO, PharmaBiome said: “The trust of Ferring in our translational approach is an important validation of our work and a unique opportunity to accelerate the development of our rationally designed consortia with an experienced market leader in the microbiome therapeutic field. We are thrilled about the complementary expertise between our companies and look forward to a fruitful collaboration.”
Based on two core technologies, PharmaBiome has developed a unique technology platform to select bacterial strains for the design of bacterial consortia as live biotherapeutic products with defined activities - the NicheMap™ and a co-cultivation approach that enables fast and scalable production. PharmaBiome’s programmes aim at a next generation of products that are independent of donor material and deliver exactly the consortium of bacterial strains with the desired activity and therapeutic effect (“defined consortia”).
Ferring is the first company to successfully bring forward a first-in-class FDA approved live microbiome-based therapy to US patients. In addition, Ferring has the proven scale and ability to drive forward clinical trials and manufacture microbiome-based products in what is a pioneering field and has a long heritage within gastroenterology.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X (Twitter).
About PharmaBiome
PharmaBiome is a biotech company developing therapeutic consortia using gut bacteria for targeted modification of microbiome composition and activity. PharmaBiome’s drug-development platform includes an in vitro culture based technology enabling the quantitative understanding of the link between microbiome composition and activity, the NicheMap™.
Discover more about PharmaBiome: www.pharmabiome.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231210383233/en/
Contact information
Matthew Worrall
Director, Corporate Communications and Public Affairs, Ferring
+447442 271811
Matthew.Worrall@ferring.com
Tomas de Wouters
CEO, PharmaBiome
+41 44 552 03 04
media@pharmabiome.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KRAFTON Records All Time Highs in Sales (2.7098T KRW) and Operating Profit (1.1825T KRW) in 202411.2.2025 08:00:00 CET | Press Release
KRAFTON, Inc. held an Investor Relations (IR) briefing on February 11, announcing its financial results for the fourth quarter and full year of 2024. According to consolidated financial statements under Korean International Financial Reporting Standards (K-IFRS), KRAFTON recorded 2.7098T KRW and operating profit (OP) of 1.1825T KRW for 2024, marking new all-time highs. These figures represent year-over-year (YoY) growth of 41.8% in sales and 54.0% in OP, driven by the continued expansion and sustainability of the PUBG IP, resulting in an average annual sales growth rate of 20% over the past five years. In the fourth quarter of 2024, KRAFTON recorded 617.6B KRW in sales and 215.5B KRW in OP, reflecting YoY increases of 15.5% and 31.1%, respectively. Key Achievements in 2024 In 2024, KRAFTON surpassed 1T KRW in operating profit for the first time since its founding. The transition of PUBG: BATTLEGROUNDS to a free-to-play model has continued to drive growth, with the game reaching a recor
Netmore Group Adds Key Hires to Drive Global Growth11.2.2025 08:00:00 CET | Press Release
Netmore Group, a leading global operator of IoT networks, announced today the addition of industry experts to its team, reinforcing its commitment to driving innovation, enabling scalable IoT deployments and meeting the growing demands of connected devices worldwide. These leaders bring extensive expertise in strategy, business development and technology, strengthening Netmore’s role in delivering scalable cloud-based solutions in the IoT connectivity market. “Massive IoT networks have the power to solve some of the most pressing global challenges—from reducing environmental impact and conservation of resources to improving quality of life,” said Ove Anebygd, CEO of Netmore Group. “With our expanded team, Netmore is well-positioned to deliver scalable and sustainable connectivity solutions that create a world where connected devices work seamlessly to transform how we live, work and manage resources.” These additions to the Netmore team are aligned with three core areas of focus to sup
EH Group Achieves ISO 9001 Certification11.2.2025 08:00:00 CET | Press Release
EH Group is proud to announce that we have secured ISO 9001 granted by leading global certification body SQS. Their rigorous audit process confirmed that our development and production processes meet the highest international standard for quality management. The implementation of this standard highlights our focus on quality and continuous improvement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210743927/en/ EH FUEL CELLS receive ISO 9001 (Graphic: Business Wire) Standards “Preparing for ISO 9001 certification has meant involving the entire team, and going to the core of our technology development and production processes. Achieving it demonstrates that we have established robust and well-defined procedures across all our business activities,” states Danny Knippen, Safety, Reliability & Certification Engineer. “The ISO 9001 certification is an important milestone for the company and shows our commitment to delivering
MammaPrint ® Reimbursement Indication Extended in Belgium11.2.2025 08:00:00 CET | Press Release
Agendia®, Inc. announced today that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement indication for MammaPrint® to include its use in the neoadjuvant setting, effective January 1, 2025. The genomic assay will now be available for full reimbursement for patients with HR+/HER2 negative early-stage breast cancer in both the pre- and postoperative settings, enabling testing on core needle biopsies for neoadjuvant treatment decisions—a pivotal advancement in providing patients with the personalized care they require. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210842892/en/ (Graphic: Business Wire) "The ability to now use MammaPrint on core needle biopsy specimen in Belgium represents a significant step for personalized treatment for women battling breast cancer," said Professor Martine Piccart, Honorary Professor of Oncology at the Université Libr
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion11.2.2025 07:17:00 CET | Press Release
Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that the company has entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the recurrence of blood clots in patients with cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210114240/en/ “Abelacimab has the potential to be an important treatment option for the millions of patients globally with atrial fibrillation at high
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom